British MPs have declared they have no faith in the government’s ten-year plan to end obesity, warning that current strategies lack core details, clear targets, and the prime minister’s personal leadership. The cross-party committee also criticised the slow rollout of weight-loss drugs, which they say forces patients into a two-tier system.
Official statistics show that 30 percent of adults in England live with obesity, and 66 percent are either overweight or living with obesity. More than a year after ministers promised to reverse rising obesity trends within a decade, the cross-party Health and Social Care Committee delivered its damning assessment in its final inquiry report on food and weight management, concluding that the government’s much-touted moonshot ambition is heading for failure, according to The Guardian.
Close to a third of children are also estimated to be affected. Written evidence submitted by researchers from Loughborough University helped inform the committee’s findings, highlighting that existing treatment services remain fragmented, unequal, and poorly equipped to prevent weight regain.
MPs Demand Personal Leadership From Prime Minister
To rescue the strategy, MPs urged the prime minister to take direct charge of the initiative. The committee called for a dedicated cabinet committee on the obesity plan, chaired by the prime minister, to send a clear signal that the government treats the health crisis as a top-tier priority.
The government will fail to tackle a challenge of this scale unless action is led from the top and delivery of the moonshot is made a clear, personal priority of the prime minister.
Health and Social Care Committee, via The Guardian
Committee chairwoman Layla Moran argued that an effective strategy requires standing up to the food industry by restricting continuous advertising and promotions for unhealthy food and drink, setting supermarket sales targets for healthy options, and giving local councils stronger authority to block new fast-food outlets near schools, as reported by Yahoo News UK.
Economic Cost of Obesity Care
The Department of Health and Social Care, citing research by Frontier Economics, estimates that obesity costs the UK economy £74.3 billion every year.
Between 2007 and 2020, primary care identified 1.8 million adults living with overweight and obesity, but only 3.13 percent of them were ever referred to a weight management programme, according to figures cited by Pulse Today. Treatment systems remain underresourced despite this massive economic footprint.
Expanding NHS Access to GLP-1 Medications
The committee heavily criticized the pace of rolling out weight-loss medications such as tirzepatide, known as Mounjaro. MPs described the current NHS rollout plan as unambitious, noting it is projected to reach only about 6 percent of eligible patients over three years, as detailed by Rayo.
This restricted availability has created a two-tier system where access depends entirely on an individual’s ability to pay for private prescriptions. To bridge the gap, the committee recommended reframing obesity as a chronic, relapsing condition managed similarly to diabetes, alongside increased capacity for bariatric surgery and greater involvement from digital health providers, as noted by Wired Gov.
People can spend their entire lives battling with their weight. We say the NHS should provide effective, structured support to beat obesity for all those who seek it. Instead, those people are repeatedly failed.
Layla Moran, Health and Social Care Committee Chair
The limited NHS supply has also inadvertently fueled a growing black market for unlicensed and counterfeit weight-loss products online. The committee urged the Medicines and Healthcare products Regulatory Agency to intensify its crackdown on illicit online sales and called for public awareness campaigns to warn consumers of the associated dangers.
In response to the report, NHS England stated that it is exploring ways to accelerate access to weight-loss medicines while prioritizing patients with the most severe and complex clinical needs, though basic questions regarding measurement and cross-departmental accountability remain unanswered by the government.